AI
Evaxion Cancer Vaccine Shows 89% Target Precision at Three Years
Evaxion reported sustained three-year immune responses and 89% target precision from a small Phase 2 EVX-01 melanoma study.
Cancer VaccineTag: Cancer Vaccine
Evaxion reported sustained three-year immune responses and 89% target precision from a small Phase 2 EVX-01 melanoma study.